Streptomyces Megacluster Yields 4 Synergistic Antibiotic Families Against Drug-Resistant E. coli
Updated
Updated · Nature.com · Jun 24
Streptomyces Megacluster Yields 4 Synergistic Antibiotic Families Against Drug-Resistant E. coli
2 articles · Updated · Nature.com · Jun 24
Summary
Researchers found a conserved Streptomyces biosynthetic megacluster that co-produces four distinct antibiotic families plus streptavidin, forming a coordinated attack on bacterial biotin metabolism rather than a single-drug system.
Those compounds hit the same pathway through complementary mechanisms—including enzyme inhibition, prodrug activation, cofactor mimicry and biotin sequestration—producing synergistic activity across Gram-negative bacteria and mycobacteria.
In a mouse model of multidrug-resistant E. coli infection, the combination of stravidin S2 and α-Me-KAPA showed stronger efficacy than either compound alone, supporting the cluster’s role as a natural combination therapy.
The study argues that higher-order gene clusters may be an overlooked antibiotic source and that drug discovery should shift from isolating single natural products to reconstructing native synergistic systems.
How did this natural antibiotic cocktail remain hidden within such well-studied bacteria?
Can this bacterial 'megacluster' be harnessed to create a new generation of superbug-killing drugs?
Synergistic Megacluster Antibiotics Targeting Biotin Metabolism: A Paradigm Shift in Combating Antimicrobial Resistance
Overview
A 2026 Nature study revealed a major breakthrough against bacterial infections by discovering a highly conserved gene megacluster in Streptomyces sp. WAC05950. This unique genetic arrangement produces a powerful mix of antibiotics that work together to disrupt bacterial biotin metabolism, a key weakness in many pathogens. By specifically inhibiting enzymes like biotin synthase and biotin ligase, these antibiotics starve bacteria of the essential biotin cofactor, crippling their growth. The coordinated, multi-pronged attack of these compounds offers a promising new strategy to combat antimicrobial resistance and paves the way for next-generation antibiotic development.